Global Pneumonia Treatment Market Report and Forecast 2024-2032

Global Pneumonia Treatment Market Outlook

The global pneumonia treatment market stood at a value of around USD 19.79 billion in 2023. The market is further expected to grow at a CAGR of 7.8% in the forecast period of 2024-2032 to attain a value of around USD 38.92 billion by 2032.         

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increased Demand for Vaccines to Drive the Market Growth of the Global Pneumonia Treatment Industry

Based on product, the vaccines segment is predicted to account for a substantial market share in the pneumonia treatment industry. This increase can be associated with the high cost of drug treatments and the growing drug resistance to many antibiotics. Moreover, with the advent and rapid implementation of pneumococcal vaccinations such as Pneumococcal conjugate vaccine (PCV13) and Pneumococcal polysaccharide vaccine (PPSV23) in the prevention of pneumonia among children below two years of age and adults above 65 years, studies indicate a large fall observed in the incidences of pneumococcal diseases in countries like the United States.

North America to Account for a Significant Market Share in the Global Pneumonia Treatment Industry

North America is expected to occupy a substantial share of the pneumonia treatment industry in the forecast period. This growth can be attributed to the growing awareness of pneumonia in the region. Moreover, with the growing geriatric population in the region, who are more susceptible to such infections, governments in the region are increasingly investing in the healthcare infrastructure to reduce mortality risks associated with pneumonia. Furthermore, a pattern of resistance to existing drugs is being observed in all age groups, which has increased the demand for subsequent research and development in the pneumonia treatments methodologies in order to create an effective cure for this disease, such as vaccines that can work for different kinds of pneumonia. These factors are expected to contribute to the industry growth significantly.

Pneumonia: Market Segmentation

Pneumonia refers to an acute respiratory infection, which inflames the air sacs in one or both lungs. These air sacs or alveoli fill up with fluids like pus, which inflames them, makes breathing painful, and limits oxygen intake. This is accompanied by symptoms like cough, fever, and chills. Pneumonia is caused by a variety of viruses, bacteria, and fungi. In addition, bacterial pneumonia is communicable through airborne droplets of coughs and sneezes. It can also spread through blood. Moreover, the severity of the disease can range from mild to life-threatening. However, pneumonia infection can be prevented through immunisation, sufficient nutrition, and addressing the environmental factors.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By product, the market is divided into:

• Drugs
• Vaccines 
• Oxygen Therapy

Among these, drugs can be further bifurcated by type into branded and generic. Out of this, the branded subtype can be further categorised, on the basis of medicine, into quinolones, aminopenicillins, macrolides, B-lactamase inhibitors, cephalosporins, tetracyclines, glycopeptide antibiotics, carbapenems, and others. At the same time, the generic subtype can be further segregated, based on medicine, into quinolones, macrolides, and others.

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Growing Geriatric Population and the Rising Incidences of Pneumonia Among Children to Augment the Growth of the Global Pneumonia Treatment Industry

According to the WHO statistics of 2019, pneumonia causes 15% of deaths of all children below five years of age worldwide. This is due to the compromised immune system of children due to malnourishment and undernutrition. In addition, any pre-existing illnesses and environmental factors such as air pollution and passive smoking are also major risk factors. Moreover, with the rapidly ageing population, more people are becoming susceptible to pneumococcal diseases. In this regard, countries worldwide and international organisations are introducing initiatives to control the spread and prevent the risks of pneumonia. For instance, the WHO and UNICEF initiative known as Global Action Plan for Pneumonia and Diarrhoea (GAPPD) aims to prevent, protect, and treat children in collaboration with several countries such as Bangladesh, Uganda, India, and Kenya. Other international institutions include the Gates Foundation, which aims to increase accessibility and the research and development of drugs and treatment through public-private funding schemes. Furthermore, with the advent of the Covid-19 infection, incidences of covid induced pneumonia are on the rise, which is expected to further augment the market growth in the forecast period.

Key Industry Players in the Global Pneumonia Treatment Market

The report gives a detailed analysis of the following key players in the global pneumonia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Pfizer Inc.
• Bayer AG
• Abbott Laboratories 
• Novartis AG
• GlaxoSmithKline Plc
• Lupin Pharmaceuticals, Inc.
• Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.

Key Highlights of the Report